AAPS PharmSciTech

, Volume 13, Issue 1, pp 134–142 | Cite as

Characterization of Oral Disintegrating Film Containing Donepezil for Alzheimer Disease

  • Kai Bin Liew
  • Yvonne Tze Fung Tan
  • Kok Khiang Peh
Research Article Theme: Advanced Technologies for Oral Controlled Release


The aim of this study was to develop a taste-masked oral disintegrating film (ODF) containing donepezil, with fast disintegration time and suitable mechanical strength, for the treatment of Alzheimer’s disease. Hydroxypropyl methylcellulose, corn starch, polyethylene glycol, lactose monohydrate and crosspovidone served as the hydrophilic polymeric bases of the ODF. The uniformity, in vitro disintegration time, drug release and the folding endurance of the ODF were examined. The in vitro results showed that 80% of donepezil hydrochloride was released within 5 minutes with mean disintegration time of 44 seconds. The result of the film flexibility test showed that the number of folding time to crack the film was 40 times, an indication of sufficient mechanical property for patient use. A single-dose, fasting, four-period, eight-treatment, double-blind study involving 16 healthy adult volunteers was performed to evaluate the in situ disintegration time and palatability of ODF. Five parameters, namely taste, aftertaste, mouthfeel, ease of handling and acceptance were evaluated. The mean in situ disintegration time of ODF was 49 seconds. ODF containing 7 mg of sucralose were more superior than saccharin and aspartame in terms of taste, aftertaste, mouthfeel and acceptance. Furthermore, the ODF was stable for at least 6 months when stored at 40°C and 75% relative humidity.


Alzheimer disease donepezil HCl oral disintegrating film palatability 



This author would like to thank Institute of Postgraduate Studies, Universiti Sains Malaysia for providing Fellowship.


  1. 1.
    Joseph TD, Robert LT, Gary CY, Gary RM, Barbara GW, Michael LP. Pharmacotherapy: a pathophysiologic approach. 6th ed. New York: McGraw Hill; 2005. p. 2162–87.Google Scholar
  2. 2.
    Martin RF. Effective pharmacologic management of Alzheimer disease. AJM. 2007;120:388–97.CrossRefGoogle Scholar
  3. 3.
    Hanawa T. Development of a new and kindly oral dosage form for elderly. JPST. 1997;13:251–8.Google Scholar
  4. 4.
    Yamamoto Y, Fujii M, Watanabe K, Tsukamoto M, Shibata Y, Kondoh M, et al. Effect of powder characteristics on oral tablet disintegration. Int J Pharm. 2009;365:116–20.PubMedCrossRefGoogle Scholar
  5. 5.
    Sunada H, Bi YX. Preparation, evaluation and optimization of rapidly disintegrating tablets. Powder Technol. 2002;122:188–98.CrossRefGoogle Scholar
  6. 6.
    Abdelbary G, Eouani C, Prinderre P, Joachim J, Reynier Jp, Piccerelle Ph. Determination of the in-vitro disintegration profile of rapidly disintegrating tablets and correlation with oral disintegration. Int J Pharm. 2005;292:29–41.PubMedCrossRefGoogle Scholar
  7. 7.
    Dixit RP, Puthli SP. Oral strip technology: overview and future potential. J Control Release. 2009;139:94–107.PubMedCrossRefGoogle Scholar
  8. 8.
    Goel H, Rai P, Rana V, Tiwary AK. Orally disintegrating systems: innovations in formulation and technology. Recent Patents on Drug Delivery and Formulation. 2008;2:258.PubMedCrossRefGoogle Scholar
  9. 9.
    Mishra R, Amin A. Formulation development of taste-masked rapidly dissolving films of cetirizine hydrochloride. Pharmtech. 2009;33(2):48–56.Google Scholar
  10. 10.
    Pillai R, Karatgi P. Orally disintegrating tablets: the path to improved patient compliance and enhanced life cycle management. Pharmtech Europe. 2009;21(5):37–41.Google Scholar
  11. 11.
    Shimoda H, Taniguchi K, Nishimura M, Matsuura K, Tsukioka T, Yamashita H, et al. Preparation of a fast dissolving oral thin film containing dexamethasone: a possible application to antiemesis during cancer chemotherapy. Eur J Pharm Sci. 2009;73:361–5.Google Scholar
  12. 12.
    Nishimura M, Matsuura K, Tsukioka T, Yamashita H, Inagaki N, Sugiyama T, et al. In vitro and in vivo characteristics of prochlorperazine oral disintegrating film. Int J Pharm. 2009;368:98–102.PubMedCrossRefGoogle Scholar
  13. 13.
    Chambin O, Champion D, Debray C, Rochat-Gonthier MH, Le Meste M, Pourcelot Y. Effects of different cellulose derivatives on drug release mechanism studied at a preformulation stage. J Control Release. 2004;95:101–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Yan YD, Jong SW, Kang JH, Yong CS, Choi HG. Preparation and evaluation of taste-masked donepezil hydrochloride orally disintegrating tablets. Biol Pharm Bull. 2010;33(8):1364–70.PubMedCrossRefGoogle Scholar
  15. 15.
    Borsadia SB, O'Halloran D, Osborne JL. Quick-dissolving films—a novel approach to drug delivery. Drug development and delivery. 2003;3(3). Available online at
  16. 16.
    Koh N, Sakamoto S, Chino F. Improvement in medication compliance and glycemic control with voglibose oral disintegrating tablet. Tohoku J Exp Med. 2008;216(3):249–57.PubMedCrossRefGoogle Scholar
  17. 17.
    Bruce JK, Angela LH, Liu H, Sara KW. Olanzapine orally disintegrating tablet in the treatment of acutely ill non-compliant patients with schizophrenia. IJNP. 2003;6:97–102.Google Scholar
  18. 18.
    Raviraj P, Pradeep K. Orally disintegrating tablets: the path to improve patient compliance and enhanced life cycle management. Pharmtech Europe. 2009;21:5.Google Scholar
  19. 19.
    Emilio MC, Vincente GG, Albert NS, Jose PF, Joan HN, Jordi GC, et al. A study on the subjective compliance and acceptance of oral lanzoprazole in traumatology. The ECOFT-TR Study. Clin Rheumatol. 2009;5(2):49–54.Google Scholar
  20. 20.
    Gohel MC, Parikh RK, Brahmbhatt BK, Shah AR. Improving the tablet characteristics and dissolution profile of ibuprofen by using a novel coprocessed superdisintegrant: a technical note. AAPS PharmSciTech. 2007;8(1):13.PubMedCrossRefGoogle Scholar
  21. 21.
    Mishra R, Amin A. Manufacturing techniques of orally dissolving films. J Pharm Sci. 2011;35(1):70–3.Google Scholar
  22. 22.
    Pappa H, Farrú R, Vilanova PO, Palacios M, Pizzorno MT. A new HPLC method to determine donepezil hydrochloride in tablets. J Pharmaceut Biomed. 2002;27:177–82.CrossRefGoogle Scholar
  23. 23.
    Japanese Pharmacopoeia 15. General tests, processes and apparatus. Tokyo, Japan: The Society of Japanese Pharmacopoeia. p. 107.Google Scholar
  24. 24.
    Cilurzo F, Cupone IE, Minghetti P, Selmin F, Montanari L. Fast dissolving films made of maltodextrins. Eur J Pharm Biopharm. 2008;70(3):895–900.PubMedCrossRefGoogle Scholar
  25. 25.
    Kuno Y, Kojima M, Andoand S, Nakagami H. Effect of preparation method on properties of orally disintegrating tablets made by phase transition. Int J Pharm. 2008;355(1–2):87–92.PubMedCrossRefGoogle Scholar
  26. 26.
    Rowe RC, Sheskey PJ, Quinn ME. Handbook of pharmaceutical excipients. 6th ed. London: Pharmaceutical Press; 2009. p. 702.Google Scholar
  27. 27.
    Doe J. 2010 Sucralose—Technological Justification. Accessed26 Oct 2010.
  28. 28.
    Rowe R, Sheskey PJ, Quinn ME. Handbook of pharmaceutical excipients. 6th ed. London: Pharmaceutical Press; 2009. p. 48.Google Scholar
  29. 29.
    Bayarri S, Izquierdo L, Costell E. Sweetening power of aspartame in hydrocolloids gels: influence of texture. Food Hydrocolloids. 2007;21:1265–74.CrossRefGoogle Scholar
  30. 30.
    Rowe RC, Sheskey PJ, Quinn ME. Handbook of pharmaceutical excipients. 6th ed. London: Pharmaceutical Press; 2009.Google Scholar
  31. 31.
    Riera CE, Vogel H, Simon SA, Coutre Jl. Artificial sweeteners and salts producing a metallic taste sensation activate TRPV1 receptors. Am J Physiol. 2007;293:626–34.Google Scholar
  32. 32.
    Okuda Y, Irisawa Y, Okimoto K, Osawa T, Yamashita S. A new formulation for orally disintegrating tablets using a suspension spray-coating method. Int J Pharm. 2009;382(1–2):80–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Chandrasekhar R, Hassan Z, AlHusban F, Smith AM, Mohammed AR. The role of formulation excipients in the development of lyophilised fast-disintegrating tablets. Eur J Pharm Biopharm. 2009;72:119–29.PubMedCrossRefGoogle Scholar
  34. 34.
    Kearney P, Rathbone MJ, Hadgraft R. The Zydis oral fast-dissolving dosage form. Modified-Release Drug Delivery Technology. 2002;2:191–201.Google Scholar
  35. 35.
    Abdelbary G, Prinderre P, Eouani C, Joachim J, Reynier JP, Piccerelle Ph. The preparation of orally disintegrating tablets using a hydrophilic waxy binder. Int J Pharm. 2004;278:423–33.PubMedCrossRefGoogle Scholar
  36. 36.
    Park TJ, Ko DH, Kim YJ, Kim YG. Polymorphic characterization of pharmaceutical solids, donepezil hydrochloride, by C CP/MAS solid-state nuclear magnetic resonance spectroscopy. B Kor Chem Soc. 2009;30(9):2007–10.CrossRefGoogle Scholar
  37. 37.
    Krishna R, Moses JB, Anil K, Chandrashekar, Vijayavitthal T, Eswaraiah S, et al. Identification and characterization of potential impurities of donepezil. J Pharmaceut Biomed. 2004;35(5):1047–58.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2011

Authors and Affiliations

  • Kai Bin Liew
    • 1
  • Yvonne Tze Fung Tan
    • 1
  • Kok Khiang Peh
    • 1
  1. 1.Department of Pharmaceutical Technology, School of Pharmaceutical SciencesUniversiti Sains MalaysiaMindenMalaysia

Personalised recommendations